Filters: keyword is inhibitors [Clear All Filters]
- 2008
Mechanistic model for the acute effect of fluvoxamine on 5-HT and 5-HIAA concentrations in rat frontal cortex,
Eur J Pharm Sci, vol. 33, no. 3, pp. 217-29.
Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats,
Br J Pharmacol, vol. 153, no. 5, pp. 1072-84.
- 2007
Population pharmacokinetic model of fluvoxamine in rats: utility for application in animal behavioral studies,
Eur J Pharm Sci, vol. 30, no. 1, pp. 45-55.
- 2006
Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers,
Br J Pharmacol, vol. 148, no. 4, pp. 396-404.
Naloxone reversal of buprenorphine-induced respiratory depression,
Anesthesiology, vol. 105, no. 1, pp. 51-7.
- 2005
Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography,
Mol Imaging Biol, vol. 7, no. 6, pp. 411-21.
Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors,
Rheumatology (Oxford), vol. 44, no. 7, pp. 846-59.
Brain penetration of synthetic adenosine A1 receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents,
Eur J Pharm Sci, vol. 24, no. 1, pp. 59-66.
- 2003
Cyclopentyladenosine and some of its low-efficacy derivatives inhibit striatal synaptosomal release of acetylcholine to a similar degree,
Eur J Pharmacol, vol. 481, no. 2-3, pp. 141-6.
Adenosine A1 receptor agonist N6-cyclopentyladenosine affects the inactivation of acetylcholinesterase in blood and brain by sarin,
J Pharmacol Exp Ther, vol. 304, no. 3, pp. 1307-13.
- 2002
Therapeutic efficacy of the adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA) against organophosphate intoxication,
Arch Toxicol, vol. 76, no. 11, pp. 650-6.
A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia,
J Pharmacol Exp Ther, vol. 300, no. 1, pp. 330-8.
- 2000
Effect of amygdala kindling on the central nervous system effects of tiagabine: EEG effects versus brain GABA levels,
Br J Pharmacol, vol. 130, no. 5, pp. 1037-44.
- 1999
Application of a combined "effect compartment/indirect response model" to the central nervous system effects of tiagabine in the rat,
J Pharmacokinet Biopharm, vol. 27, no. 3, pp. 301-23.
- 1998
Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of draflazine,
J Pharmacol Exp Ther, vol. 286, no. 1, pp. 142-9.
- 1997
Population analysis of the non-linear red blood cell partitioning of draflazine following various infusion durations,
Eur J Clin Pharmacol, vol. 53, no. 1, pp. 57-63.
- 1996
The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine,
Br J Clin Pharmacol, vol. 42, no. 5, pp. 605-13.
Pharmacokinetic-haemodynamic relationships of 2-chloroadenosine at adenosine A1 and A2a receptors in vivo,
Br J Pharmacol, vol. 118, no. 2, pp. 369-77.
- 1992
In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil,
J Pharmacol Exp Ther, vol. 260, no. 1, pp. 36-44.
Pharmacokinetic considerations on Orgaran (Org 10172) therapy,
Haemostasis, vol. 22, no. 2, pp. 73-84.
- 1991
Interaction study between Org 10172, a low molecular weight heparinoid, and acetylsalicylic acid in healthy male volunteers,
Thromb Haemost, vol. 66, no. 2, pp. 202-7.
Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity,
J Pharmacol Exp Ther, vol. 257, no. 1, pp. 472-8.



